Form 4: Twist Bioscience Exec Sells Shares Under 10b5-1 Plan

Dennis Cho, Senior Vice President at Twist Bioscience, reported a sale of 14,205 shares of common stock on June 24, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 14,205 shares of common stock.
• The transaction occurred on June 24, 2026.
• The sale price was $89.75 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2026.
• Following the transaction, Mr. Cho beneficially owns 105,141 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although it was conducted under a pre-planned 10b5-1 trading plan, mitigating immediate negative sentiment.

Negatives

• Company executive sold a significant number of shares.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a report of a past transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common for executives to diversify holdings or manage personal finances. However, the volume and timing relative to company performance can be a signal to the market.

Stakeholder Impact

• Shareholders may view the executive's sale as a potential indicator of future stock performance, although the Rule 10b5-1 plan suggests it was pre-planned and not necessarily based on non-public information.

Key Dates

Keywords

Twist Bioscience, TWST, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Common Stock, Dennis Cho